A systematic review found that driving-related performance under psychiatric medication depended on the drug, illness, and duration of treatment.
What the source reports
Forty studies involving 1,533 patients were reviewed. Diazepam worsened driving during the first weeks after initiation in included evidence, while some longer-term treated groups showed no evident on-road impairment. The review also covered antidepressants and antipsychotics and emphasized stabilization during treatment.
Limits of the evidence
More than 60% of the included studies were cross-sectional or open-label. Samples and tests varied, making it difficult to separate illness from medication effects. Lack of an observed deficit in selected long-term users is not proof of universal tolerance or safe driving.
Implications for forensic review
An individual driving opinion should address initiation, dose changes, duration, concurrent substances, sleep, and actual observations. This review argues against treating every prescription as an identical exposure. It does not supply a universal concentration cutoff or guarantee normal performance in an experienced user.
Source and related reading
Source reviewed: Driving Performance Under Treatment of Most Frequently Prescribed Drugs for Mental Disorders A Syste (PMC8453274). This article summarizes the supplied paper; forensic applications above are interpretive analysis.
Related reading: Clobazam Interaction Review Shows Why Measuring the Active Metabolite Matters; Cirrhosis Deprescribing Interviews Identify Barriers, Not Proof That Stopping Benzodiazepines Prevents Encephalopathy.
Leave a Reply